A novel physiological property of snake bradykinin-potentiating peptides-Reversion of MK-801 inhibition of nicotinic acetylcholine receptors

Peptides

Volumn 29, Issue 10, 2008, Pages 1708-1715

  Nery, Arthur A ^a   Trujillo, Cleber A ^a   Lameu, Claudiana ^a,b   Konno, Katsuhiro ^b   Oliveira, Vitor ^c   Camargo, Antonio C M ^b   Ulrich, Henning ^a   Hayashi, Mirian A F ^b,c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO BUTANTAN   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bradykinin potentiating peptides; MK 801 inhibition; Nicotinic acetylcholine receptor; PC12 pheochromocytoma cells

Indexed keywords

BRADYKININ POTENTIATING PEPTIDE; CARBACHOL; DIPEPTIDYL CARBOXYPEPTIDASE; DIZOCILPINE; NICOTINIC RECEPTOR; OLIGOPEPTIDE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL STRAIN; DOSE RESPONSE; DRUG ANTAGONISM; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; NERVE CELL DIFFERENTIATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; SNAKE;

ANIMALS; BOTHROPS; BRADYKININ; CARBACHOL; CHOLINERGIC AGONISTS; CROTALID VENOMS; DIZOCILPINE MALEATE; HUMANS; NICOTINIC ANTAGONISTS; PATCH-CLAMP TECHNIQUES; PC12 CELLS; PEPTIDES; PROTEIN SUBUNITS; RATS; RECEPTORS, NICOTINIC;

BOTHROPS JARARACA; VIPERINAE;

EID: 52249091997     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2008.06.002     Document Type: Article

References (60)

1. Asselbergs F.W., and van Gilst W.H. Angiotensin converting enzyme inhibition in cardiovascular risk populations: a practical approach to identify the patient who will benefit most. Curr Opin Cardiol 22 (2007) 267-272
2. Barat S.A., and Abdel-Rahman M.S. Cocaine and lidocaine in combination are synergistic convulsants. Brain Res 742 (1996) 157-162
3. Black C.E., Huang N., Neligan P.C., Levine R.H., Lipa J.E., Lintlop S., et al. Effect of nicotine on vasoconstrictor and vasodilator responses in human skin vasculature. Am J Physiol Regul Integr Comp Physiol 281 (2001) 1097-1104
4. Bruggmann D., Lips K.S., Pfeil U., Haberberger R.V., and Kummer W. Multiple nicotinic acetylcholine receptor alpha-subunits are expressed in the arterial system of the rat. Histochem Cell Biol 118 (2002) 441-447
5. Cheung-Wu C., Mao-Ying W., Shan-Shan L., and Ting-Hwo C. Structure-function studies on the bradykinin potentiating peptide from Chinese snake venom (Agkistrodon halys pallas). Agents Actions 9 (1982) 282-288
6. Chow H.S., Chen Z., and Matsuura G.T. Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats. J Pharm Sci 88 (1999) 754-758
7. Cintra A.C.O., Vieira C.A., and Giglio J.R. Primary structure and biological activity of bradykinin potentiating peptides from Bothrops insularis snake venom. J Prot Chem 9 (1990) 221-227
8. Collier J.G., Robinson B.F., and Vane J.R. Reduction of pressor effects of angiotensin I in man by synthetic nonapeptide (B.P.P. 9a or SQ 20,881) which inhibits converting enzyme. Lancet 1 (1973) 72-74
9. Conceição K., Konno K., de Melo R.L., Antoniazzi M.M., Jared C., Sciani J.M., et al. Isolation and characterization of a novel bradykinin potentiating peptide (BPP) from the skin secretion of Phyllomedusa hypochondrialis. Peptides 28 (2007) 515-523
10. Cotton J., Hayashi M.A., Cuniasse P., Vazeux G., Ianzer D., Camargo A.C., et al. Selective inhibition of the C-domain of angiotensin I converting enzyme by bradykinin potentiating peptides. Biochemistry 41 (2002) 6065-6071
11. Cui Y., Ulrich H., and Hess G.P. Selection of 2′-fluoro-modified RNA aptamers for alleviation of cocaine and MK-801 inhibition of the nicotinic acetylcholine receptor. J Membr Biol 202 (2004) 137-149
12. Cushman D.W., Cheung H.S., Sabo E.F., and Ondetti M.A. Development and design of specific inhibitors of angiotensin-converting enzyme. Am J Cardiol 49 (1982) 1390-1394
13. Cushman D.W., Ondetti M.A., Gordon E.M., Natarajan S., Karanewsky D.S., Krapcho J., et al. Rational design and biochemical utility of specific inhibitors of angiotensin-converting enzyme. J Cardiovasc Pharmacol 10 (1987) 17-30
14. De Biasi M. Nicotinic receptor mutant mice in the study of autonomic function. Curr Drug Targets CNS Neurol Disord 1 (2002) 331-336 [Review]
15. Ferrari R., Bertrand M.E., Remme W.J., Simoons M.L., Deckers J.W., and Fox K.M. Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial. Expert Rev Cardiovasc Ther 5 (2007) 1037-1046
16. Ferreira L.A., Auer H., Haslinger E., Fedele C., and Habermehl G.G. Spatial structures of the bradykinin potentiating peptide F from Agkistrodon piscivorus piscivoris venom. Toxicon 37 (1999) 661-676
17. Ferreira L.A., Galle A., Raida M., Schrader M., Lebrun I., and Habermehl G. Isolation: analysis and properties of three bradykinin-potentiating peptides (BPP-II, BPP-III, and BPP-V) from Bothrops neuwiedi venom. J Protein Chem 17 (1998) 285-289
18. Ferreira L.A., Henriques O.B., Lebrun I., Batista M.B., Prezoto B.C., Andreoni A.S., et al. A new bradykinin-potentiating peptide (peptide P) isolated from the venom of Bothrops jararacuçu (Jararacucu tapete, Urutu dourado). Toxicon 30 (1992) 33-40
19. Ferreira L.A., Henriques O.B., Lebrun I., Batista M.B., Prezoto B.C., Andreoni A.S., et al. Biologically active peptides from Bothrops jararacussu venom. Agents Actions Suppl 36 (1992) 209-214
20. Ferreira L.A., Mollring T., Lebrun F.L., Raida M., Znottka R., and Habermehl G.G. Structure and effects of a kinin potentiating fraction F (AppF) isolated from Agkistrodon piscivorus piscivorus venom. Toxicon 33 (1995) 1313-1319
21. Ferreira S.H., Bartelt D.C., and Greene L.J. Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom. Biochemistry 9 (1970) 2583-2593
22. Ferreira S.H., Greene L.H., Alabaster V.A., Bakhle Y.S., and Vane J.R. Activity of various fractions of bradykinin potentiating factor against angiotensin I converting enzyme. Nature 225 (1970) 379-380
23. Furchgott R.F., and Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288 (1980) 373-376
24. Gavras H., Brunner H.R., Laragh J.H., Searley S.E., Gavras I., and Vukovich R.A. An angiotensin converting enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N Engl J Med 291 (1974) 817-821
25. Gomes C.L., Konno K., Conceição I.M., Ianzer D., Yamanouye N., Prezoto B.C., et al. Identification of novel bradykinin-potentiating peptides (BPPs) in the venom gland of a rattlesnake allowed the evaluation of the structure-function relationship of BPPs. Biochem Pharmacol 74 (2007) 1350-1360
26. Graham R.L.J., Graham C., McClean S., Chen T., O'Rourke M., Hirst D., et al. Identification and functional analysis of a novel bradykinin inhibitory peptide in the venoms of New World Crotalinae pit vipers. Biochem Biophys Res Commun 338 (2005) 1587-1592
27. Hawkins B.T., Egleton R.D., and Davis T.P. Modulation of cerebral microvascular permeability by endothelial nicotinic acetylcholine receptors. Am J Physiol Heart Circ Physiol 289 (2005) 212-219
28. Hayashi M.A., and Camargo A.C. The bradykinin-potentiating peptides from venom gland and brain of Bothrops jararaca contain highly site specific inhibitors of the somatic angiotensin-converting enzyme. Toxicon 45 (2005) 1163-1170
29. Hayashi M.A., Murbach A.F., Ianzer D., Portaro F.C., Prezoto B.C., Fernandes B.L., et al. The C-type natriuretic peptide precursor of snake brain contains highly specific inhibitors of the angiotensin-converting enzyme. J Neurochem 85 (2003) 969-977
30. Henderson L.P., Gdovin M.J., Liu C., Gardner P.D., and Maue R.A. Nerve growth factor increases nicotinic ACh receptor gene expression and current density in wild-type and protein kinase A-deficient PC12 cells. J Neurosci 14 (1994) 1153-1163
31. Herz J.M., Johnson D.A., and Taylor P. Distance between the agonist and noncompetitive inhibitor sites on the nicotinic acetylcholine receptor. J Biol Chem 264 (1989) 12439-12448
32. Hess G.P., Gameiro A.M., Schoenfeld R.C., Chen Y., Ulrich H., Nye J.A., et al. Reversing the action of non-competitive inhibitors (MK-801 and cocaine) on a protein (nicotinic acetylcholine receptor) mediated reacted. Biochemistry 42 (2003) 6106-6114
33. Hess G.P., and Grewer C. Development and application of caged ligands for neurotransmitter receptors in transient kinetic and neuronal circuit mapping studies. Methods Enzymol 291 (1998) 443-473 [Review]
34. Hess G.P., Ulrich H., Breitinger H.G., Niu L., Gameiro A.M., Grewer C., et al. Mechanism-based discovery of ligands that counteract inhibition of the nicotinic acetylcholine receptor by cocaine and MK-801. Proc Natl Acad Sci USA 97 (2000) 13895-13900
35. Hess G.P. Determination of the chemical mechanism of neurotransmitter receptor-mediated reactions by rapid chemical kinetic methods. Arch Physiol Biochem 104 (1996) 752-761 [Review]
36. Higuchi S., Murayama N., Saguchi K., Ohi H., Fujita Y., Camargo A.C., Ogawa T., et al. Bradykinin-potentiating peptides and C-type natriuretic peptides from snake venom. Immunopharmacology 44 (1999) 129-135
37. Ianzer D., Konno K., Marques-Porto R., Portaro F.C.V., Stöcklin R., Camargo A.C.M., et al. Identification of five new bradykinin potentiating peptides (BPPs) from Bothrops jararaca crude venom by using electrospray ionization tandem mass spectrometry after a two-step liquid chromatography. Peptides 25 (2004) 1085-1092
38. Ianzer D., Santos R.A., Etelvino G.M., Xavier C.H., de Almeida Santos J., Mendes E.P., et al. Do the cardiovascular effects of angiotensin-converting enzyme (ACE) I involve ACE-independent mechanisms? New insights from proline-rich peptides of Bothrops jararaca. J Pharmacol Exp Ther 322 (2007) 795-805
39. Jaspard E., Wei L., and Alhenc-Gelas F. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J Biol Chem 268 (1993) 9496-9503
40. Kalaria R.N., Homayoun P., and Whitehouse P.J. Nicotinic cholinergic receptors associated with mammalian cerebral vessels. J Auton Nerv Syst 49 (1994) 3-7
41. Karpen J.W., and Hess G.P. Cocaine, phencyclidine, and procaine inhibition of the acetylcholine receptor: characterization of the binding site by stopped-flow measurements of receptor-controlled ion flux in membrane vesicles. Biochemistry 25 (1986) 1777-1785
42. Kato H., and Suzuki T. Bradykinin-potentiating peptides from the venom of Agkistrodon halys blomhoffi. Isolation of five bradykinin potentiators and the amino acid sequences of two of them, potentiators B and C. Biochemistry 10 (1971) 972-980
43. Kato H., and Suzuki T. Structure of bradykinin-potentiating peptide containing tryptophan from the venom of Agkistrodon halys blomhoffii. Experientia 26 (1970) 1205-1206
44. Krishtal O., and Pidoplichko V.I. A receptor for protons in the nerve cell membrane. Neuroscience 5 (1980) 2324-2327
45. Krivoshein A.V., and Hess G.P. Mechanism-based approach to the successful prevention of cocaine inhibition of the neuronal (alpha 3 beta 4) nicotinic acetylcholine receptor. Biochemistry 43 (2004) 481-489
46. Magdesian M.H., Nery A.A., Martins A.H., Juliano M.A., Juliano L., Ulrich H., et al. Peptide blockers of the inhibition of neuronal nicotinic acetylcholine receptors by amyloid beta. J Biol Chem 280 (2005) 31085-31090
47. Murayama N., Hayashi M.A.F., Ohi H., Ferreira L.A.F., Hermann V.V., Saito H., et al. Cloning and sequence analysis of a Bothrops jararaca cDNA encoding a precursor of seven bradykinin-potentiating peptides and a C-type natriuretic peptide. Proc Natl Acad Sci USA 94 (1997) 1189-1193
48. Politi V., De Luca G., Di Stazio G., Schinina E., and Bossa F. A new peptide from Crotalus atrox snake venom. Peptides 6 (1985) 343-346
49. Rocha e Silva M., Beraldo W.T., and Rosenfeld G. Bradykinin hypotensive and smooth muscle stimulating factor released from plasma globulins by snake venoms and by trypsin. Am J Physiol 156 (1949) 261-273
50. Rogers S.W., Mandelzys A., Deneris E.S., Cooper E., and Heinemann S. The expression of nicotinic acetylcholine receptors by PC12 cells treated with NGF. J Neurosci 12 (1992) 4611-4623
51. Rousseau A., Michaud A., Chauvet M.T., Lenfant M., and Corvol P. The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J Biol Chem 270 (1995) 3656-3661
52. Tischcler A.S., and Greene L.A. Nerve growth factor-induced process formation by cultured rat pheochromocytoma cells. Nature 258 (1975) 341-342
53. Udgaonkar J.B., and Hess G.P. Chemical kinetic measurements of a mammalian acetylcholine receptor using a fast reaction technique. Proc Natl Acad Sci USA 84 (1987) 8758-8762
54. Ufkes J.G., Aarsen P.N., and van der Meer C. The mechanism of action of two bradykinin-potentiating peptides on isolated smooth muscle. Eur J Pharmacol 44 (1977) 89-97
55. Ulrich H., Akk G., Nery A.A., Trujillo C.A., Rodriguez A.D., and Eterovic V.A. Mode of cembranoid action on embryonic muscle acetylcholine receptor. J Neurosci Res 86 (2008) 93-107
56. Ulrich H., Ippolito J.E., Pagan O.R., Eterovic V.E., Hann R.M., Shi H., et al. In vitro selection of RNA molecules that displace cocaine from the membrane-bound nicotinic acetylcholine receptor. Proc Natl Acad Sci USA 95 (1998) 14051-14056
57. Unwin N. Refined structure of the nicotinic acetylcholine receptor at 4A resolution. J Mol Biol 346 (2005) 967-989
58. Villard E., and Soubrier F. Molecular biology and genetics of the angiotensin-I-converting enzyme: potential implications in cardiovascular diseases. Cardiovasc Res 32 (1996) 999-1007 [Review]
59. White H.D. Should all patients with coronary disease receive angiotensin converting-enzyme inhibitors?. Lancet 362 (2003) 755-757
60. Wickett R., Li H.J., and Isenberg I. Use of intrinsic protein fluorescence to study DNA-protein binding. Anal Biochem 50 (1972) 608-611